Biogen Wins China Approval for At-Home Alzheimer’s Treatment
Biogen won China NMPA approval for a self-administered, weekly at-home LEQEMBI dose for early Alzheimer's, expanding access and reinforcing its strategy to simplify treatment in real-world settings. At a Morgan Stanley healthcare conference, Biogen executives discussed ongoing business reshaping and active business development as part of their strategic pivot.
Business · 16 sources · Sep 16, 2026Read it
The journal
Open the journal →The conversation starts in the journal — be the first to post.
About Biogen
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
Everything about Biogen →- Country
- United States
- Headquarters
- Cambridge
- Inception
- 1978
- Website
- https://www.biogen.com/